Heterocyclic compounds play a crucial role in medicinal chemistry, with imidazo1,2-apyridine emerging as a significant scaffold due to its broad pharmacological applications. The unique structural framework of imidazo1,2-apyridine allows for strong interactions with biological targets, making it a favorable candidate for anticancer drug development. This review explores the recent advancements in the synthesis, structure-activity relationship (SAR), and mechanistic insights of imidazo1,2-apyridine derivatives as anticancer agents. Various synthetic methodologies, including multicomponent reactions and named transformations, have facilitated the generation of diverse derivatives with potent biological activity. The anticancer properties of these compounds stem from their ability to modulate key signaling pathways, induce apoptosis, and inhibit kinases implicated in tumor progression. Additionally, we discuss cytotoxic evaluations and the therapeutic potential of these derivatives against different cancer cell lines. The review highlights the challenges and future perspectives in optimizing imidazo1,2-apyridine-based compounds for clinical applications, emphasizing their promise as next-generation anticancer therapeutics.
Shah et al. (Sun,) studied this question.